FMT
ESPR

First Mercantile Trust’s Esperion Therapeutics ESPR Stock Holding History

First Mercantile Trust’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,771
Closed -$345K – 933
2018
Q1 		$345K Buy
4,771
+538
+13% +$39.5K 0.07% 331
2017
Q4 		$279K Buy
4,233
+1,519
+56% +$81.8K 0.05% 431
2017
Q3 		$136K Buy
+2,714
New +$131K 0.02% 648
2016
Q2 		– Sell
-10,054
Closed -$170K – 888
2016
Q1 		$170K Sell
10,054
-1,468
-13% -$23.6K 0.02% 614
2015
Q4 		$256K Buy
11,522
+2,167
+23% +$54.7K 0.03% 606
2015
Q3 		$221K Buy
9,355
+1,900
+25% +$119K 0.02% 638
2015
Q2 		$610K Buy
7,455
+2,200
+42% +$215K 0.05% 440
2015
Q1 		$487K Buy
+5,255
New +$339K 0.04% 505

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

First Mercantile Trust's ESPR Position: Q2 2018 in Review

First Mercantile Trust sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 4,771 shares — an estimated $345K sold.

First Mercantile Trust first reported a position in ESPR in Q1 2015 and held it in 8 quarters. The position peaked at $610K in Q2 2015. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

  • First Mercantile Trust reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
  • First Mercantile Trust sold 4,771 Esperion Therapeutics shares in Q2 2018, an estimated $345K.
  • First Mercantile Trust first reported a position in Esperion Therapeutics in Q1 2015 and held it in 8 quarters.
  • First Mercantile Trust's Esperion Therapeutics position peaked at $610K in Q2 2015.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on First Mercantile Trust's 13F filing for Q2 2018, filed 26 Jul 2018.